Development and Clinical Trials of Nucleic Acid Medicines for Pancreatic Cancer Treatment.

Abstract

Approximately 30% of pancreatic cancer patients harbor targetable mutations. However, there has been no therapy targeting these molecules clinically. Nucleic acid medicines show high specificity and can target RNAs. Nucleic acid medicine is expected to be the next-generation treatment next to small molecules and antibodies. There are several kinds of nucleic acid drugs, including antisense oligonucleotides, small interfering RNAs, microRNAs, aptamers, decoys, and CpG oligodeoxynucleotides. In this review, we provide an update on current research of nucleic acid-based therapies. Despite the challenging obstacles, we hope that nucleic acid drugs will have a significant impact on the treatment of pancreatic cancer. The combination of genetic diagnosis using next generation sequencing and targeted therapy may provide effective precision medicine for pancreatic cancer patients.

• Authors: Keiko Yamakawa, Yuko Nakano-Narusawa, Nozomi Hashimoto, Masanao Yokohira, Yoko Matsuda
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 20 Issue 17 (Aug 29 2019) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 31470511 (Publication Type: Journal Article, Review)

Chemical References

• Aptamers, Nucleotide
• Oligodeoxyribonucleotides
• Oligonucleotides, Antisense
• RNA, Neoplasm
• RNA, Small Interfering

Topics

• Animals
• Aptamers, Nucleotide (genetics, therapeutic use)
• Clinical Trials as Topic (methods)
• Humans
• Oligodeoxyribonucleotides (genetics, therapeutic use)
• Oligonucleotides, Antisense (genetics, therapeutic use)
• Pancreatic Neoplasms (drug therapy, genetics, pathology)
• RNA, Neoplasm (antagonists & inhibitors, genetics)
• RNA, Small Interfering (genetics, therapeutic use)